Foghorn Therapeutics Inc.
FHTXHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin. The company carries a $286.8M market cap, placing it firmly in the micro-cap category. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Market Cap
$286.8M
Beta
2.86
P/E (TTM)
—
P/E (Fwd)
-4.43
EPS (TTM)
$-0.99
EPS (Fwd)
$-1.09
ROE
—
ROA
-19.9%
Cash
$167.6M
Total Debt
$43.1M
Free CF
-$52.0M
52W Change
-4.5%
Annual Financials
Cash vs Debt
Where FHTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FHTX finished 1.57% above its 150-day moving average ($5.09) and 1.17% above its 200-day moving average ($5.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FHTX overbought or oversold?
At the September 3, 2026 close, FHTX's RSI(14) was 28.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Foghorn Therapeutics Inc. holds $167.6M in cash against $43.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$52.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $19.2M (2022) to $30.9M (2025), reflecting a 61% increase over the period.
With a beta above 1.5, FHTX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, FHTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Foghorn Therapeutics Inc. and its sector.